Literature DB >> 11276379

Update on familial pancreatic cancer.

H T Lynch1, R E Brand, C A Deters, R M Fusaro.   

Abstract

Approximately 5% to 10% of patients with pancreatic cancer have one or more first-degree relatives with this disease. A subset of these individuals have a hereditary form of pancreatic cancer designated by association with such hereditary disorders as familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, hereditary pancreatitis, or familial atypical multiple mole melanoma (FAMMM) syndrome. A subset of those FAMMM kindred with the CDKN2A (p16) germline mutation that expresses both pancreatic cancer and malignant melanoma may constitute a new hereditary pancreatic cancer-prone syndrome.

Entities:  

Mesh:

Year:  2001        PMID: 11276379     DOI: 10.1007/s11894-001-0008-5

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  52 in total

1.  Registers for patients with familial tumours: from controversial areas to common guidelines.

Authors:  C J Lips
Journal:  Br J Surg       Date:  1998-10       Impact factor: 6.939

2.  Total pancreatectomy for ductal adenocarcinoma of the pancreas: an update.

Authors:  J A van Heerden; D C McIlrath; D M Ilstrup; L H Weiland
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

Review 3.  Familial pancreatic cancer: a review.

Authors:  H T Lynch; T Smyrk; S E Kern; R H Hruban; C J Lightdale; S J Lemon; J F Lynch; L R Fusaro; R M Fusaro; P Ghadirian
Journal:  Semin Oncol       Date:  1996-04       Impact factor: 4.929

4.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Authors:  M Schutte; R H Hruban; J Geradts; R Maynard; W Hilgers; S K Rabindran; C A Moskaluk; S A Hahn; I Schwarte-Waldhoff; W Schmiegel; S B Baylin; S E Kern; J G Herman
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

5.  Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.

Authors:  A M Goldstein; J P Struewing; A Chidambaram; M C Fraser; M A Tucker
Journal:  J Natl Cancer Inst       Date:  2000-06-21       Impact factor: 13.506

6.  Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer.

Authors:  P Berthélemy; M Bouisson; J Escourrou; N Vaysse; J L Rumeau; L Pradayrol
Journal:  Ann Intern Med       Date:  1995-08-01       Impact factor: 25.391

7.  Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma.

Authors:  M Tada; M Omata; S Kawai; H Saisho; M Ohto; R K Saiki; J J Sninsky
Journal:  Cancer Res       Date:  1993-06-01       Impact factor: 12.701

8.  Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada.

Authors:  P Ghadirian; P Boyle; A Simard; J Baillargeon; P Maisonneuve; C Perret
Journal:  Int J Pancreatol       Date:  1991 Nov-Dec

9.  Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma.

Authors:  E Brockie; A Anand; J Albores-Saavedra
Journal:  Ann Diagn Pathol       Date:  1998-10       Impact factor: 2.090

10.  Systemic cancer and the FAMMM syndrome.

Authors:  W Bergman; P Watson; J de Jong; H T Lynch; R M Fusaro
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

View more
  1 in total

Review 1.  Genetic alterations in pancreatic cancer.

Authors:  Muhammad Wasif Saif; Lena Karapanagiotou; Kostas Syrigos
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.